<DOC>
	<DOCNO>NCT00004162</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness liposomal doxorubicin plus combination chemotherapy treat patient AIDS-associated non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Liposomal Doxorubicin Plus Combination Chemotherapy Treating Patients With AIDS-Associated Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity maximum tolerate dose doxorubicin HCl liposome administer combination chemotherapy patient AIDS-associated non-Hodgkin 's lymphoma . II . Determine optimal phase II dose doxorubicin HCl liposome administer combination chemotherapy regimen . III . Determine effect regimen HIV viral load patient . IV . Determine clinical response regimen patient . OUTLINE : This dose escalation study doxorubicin HCl liposome . Patients stratify risk group ( good v poor ) . Patients receive doxorubicin HCl liposome IV , vincristine IV , methotrexate intrathecally day 1 , follow oral prednisone day 1-5 . Sargramostim ( GM-CSF ) administer subcutaneously day 5-14 blood count recover . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos doxorubicin HCl liposome maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A minimum 42-48 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven good poor prognosis AIDSassociated nonHodgkin 's lymphoma express CD20 antigen HIV positive Stage IIIV Good risk patient define : Karnofsky 80100 % No prior history AIDS defining illness No bone marrow involvement lymphoma No clinical , radiographic , cytologic evidence CNS lymphoma Bidimensionally measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80100 % Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 75,000/mm3 Hemoglobin great 9 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT less 5 time ULN Alkaline phosphatase less 5 time ULN Renal : Creatinine great 1.5 time ULN Other : Not pregnant No active opportunistic serious infection No malignancy ( include AIDSassociated malignancy ) except stable cutaneous Kaposi 's sarcoma No serious medical psychiatric condition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior doxorubicin doxorubicin HCl liposome No prior chemotherapy nonHodgkin 's lymphoma , except single dose intrathecal chemotherapy time stag lumbar puncture Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : At least 2 week since major surgery Other : No concurrent treatment Kaposi 's sarcoma Concurrent antiretroviral therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
</DOC>